Macquarie Group Ltd. boosted its holdings in shares of Retrophin, Inc. (NASDAQ:RTRX) by 17.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,188,819 shares of the biopharmaceutical company’s stock after buying an additional 172,389 shares during the quarter. Macquarie Group Ltd. owned 3.10% of Retrophin worth $23,051,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in RTRX. Nationwide Fund Advisors lifted its holdings in Retrophin by 129.9% during the 1st quarter. Nationwide Fund Advisors now owns 51,841 shares of the biopharmaceutical company’s stock worth $957,000 after buying an additional 29,290 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Retrophin by 12.8% in the 1st quarter. Wells Fargo & Company MN now owns 50,785 shares of the biopharmaceutical company’s stock valued at $938,000 after purchasing an additional 5,763 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Retrophin by 14,062.4% in the 1st quarter. JPMorgan Chase & Co. now owns 131,852 shares of the biopharmaceutical company’s stock valued at $2,434,000 after purchasing an additional 130,921 shares in the last quarter. American International Group Inc. raised its holdings in shares of Retrophin by 7.1% in the 1st quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 1,475 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Retrophin in the 1st quarter valued at $219,000.
TRADEMARK VIOLATION NOTICE: “Macquarie Group Ltd. Grows Holdings in Retrophin, Inc. (RTRX)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://sportsperspectives.com/2017/10/12/macquarie-group-ltd-grows-holdings-in-retrophin-inc-rtrx.html.
A number of equities research analysts have recently weighed in on RTRX shares. ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a report on Monday, July 17th. BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Finally, BMO Capital Markets restated a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a report on Friday, October 6th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $36.00.
Shares of Retrophin, Inc. (RTRX) opened at 24.26 on Thursday. The stock has a 50 day moving average of $24.03 and a 200-day moving average of $20.26. Retrophin, Inc. has a one year low of $15.55 and a one year high of $25.44. The firm’s market capitalization is $931.22 million.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). The firm had revenue of $38.80 million during the quarter, compared to analysts’ expectations of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. Retrophin’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.07 earnings per share. On average, equities analysts anticipate that Retrophin, Inc. will post ($1.13) earnings per share for the current fiscal year.
In related news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the sale, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at $306,495. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.41% of the company’s stock.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.